Skip to main content

and
  1. Article

    Open Access

    Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

    Brett King, Jennifer Soung, Christos Tziotzios in American Journal of Clinical Dermatology (2024)

  2. Article

    Open Access

    Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

    The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA).

    Brett King, Jennifer Soung, Christos Tziotzios in American Journal of Clinical Dermatology (2024)

  3. No Access

    Article

    Oceanic internal solitary waves at the Indonesian submarine wreckage site

    Yankun Gong, Jieshuo **e, Jiexin Xu, Zhiwu Chen, Yinghui He in Acta Oceanologica Sinica (2022)